Sanofi inks marketing pact with Emcure for cancer drugs

Tags: Companies
Drug firm Sanofi has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India.

As per the agreement, Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, while Emcure will market and distribute these brands through its specialty unit, Sanofi India said in a filing to the BSE.

"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," Sanofi Vice-President-South Asia and Sanofi India Managing Director Shailesh Ayyangar said.

Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business, he added.

Emcure Pharmaceuticals Managing Director Satish Mehta said: "We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions."

Sanofi India Ltd shares were trading at Rs 2,886 a piece on the BSE in afternoon trade, up 0.27% from its previous close.

EDITORIAL OF THE DAY

  • RBI must join hands with IRDAI to stop misselling of insurance by banks

    Reserve Bank of India (RBI) governor Raghuram Rajan has observed in the annual report for 2015-16 released on Monday that the central bank will be foc

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Roopen Roy

Streaming indeed has a bright future

Woody Allen has turned 80. But his energy has not ...

Zehra Naqvi

How much land does a man need?

“When the blood in your veins returns to the sea ...

Dharmendra Khandal

Everything has its place in nature

Last week I was observing an injured animal, because of ...